TW307769B - - Google Patents
Download PDFInfo
- Publication number
- TW307769B TW307769B TW082105942A TW82105942A TW307769B TW 307769 B TW307769 B TW 307769B TW 082105942 A TW082105942 A TW 082105942A TW 82105942 A TW82105942 A TW 82105942A TW 307769 B TW307769 B TW 307769B
- Authority
- TW
- Taiwan
- Prior art keywords
- hydrochloride
- patent application
- water
- crystalline hydrate
- hydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20496592 | 1992-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW307769B true TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1997-06-11 |
Family
ID=16499234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW082105942A TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-07-31 | 1993-07-26 |
Country Status (23)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1368349E (pt) * | 2001-02-24 | 2007-04-30 | Boehringer Ingelheim Pharma | Derivados de xantina, sua preparação e sua utilização como medicamento |
AT413282B (de) * | 2002-02-01 | 2006-01-15 | Sandoz Ag | Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl) |
KR20030076759A (ko) * | 2002-03-21 | 2003-09-29 | 주식회사 엘지생명과학 | 신규 세팔로스포린 화합물 및 그의 제조 방법 |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US6727277B1 (en) | 2002-11-12 | 2004-04-27 | Kansas State University Research Foundation | Compounds affecting cholesterol absorption |
JP5192147B2 (ja) | 2003-02-12 | 2013-05-08 | 日産化学工業株式会社 | ピタバスタチンカルシウムの結晶質形態 |
BRPI0408716B1 (pt) | 2003-03-27 | 2017-08-29 | Basilea Pharmaceutica Ag. | Cefalosporin in crystalline form, process for its preparation and its uses, and preparation of cephalosporin |
US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
PE20110235A1 (es) * | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
ES2733348T3 (es) * | 2007-08-17 | 2019-11-28 | Boehringer Ingelheim Int | Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
EP2326326B1 (en) * | 2008-08-15 | 2019-10-09 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients |
WO2010029089A2 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
PT2566469T (pt) | 2010-05-05 | 2023-01-10 | Boehringer Ingelheim Int | Terapia de combinação |
JP5843855B2 (ja) | 2010-06-24 | 2016-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病療法 |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
EP2849754B1 (en) | 2012-05-14 | 2022-09-14 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES475573A1 (es) * | 1977-07-12 | 1980-01-16 | Fujisawa Pharmaceutical Co | Un procedimiento para preparar nuevos compuestos de cefem |
IE65926B1 (en) * | 1990-07-19 | 1995-11-29 | Shionogi & Co | Thioalkylthio cephalosporin derivatives |
-
1993
- 1993-07-26 EP EP93305864A patent/EP0581552B1/en not_active Expired - Lifetime
- 1993-07-26 ES ES93305864T patent/ES2115725T3/es not_active Expired - Lifetime
- 1993-07-26 TW TW082105942A patent/TW307769B/zh active
- 1993-07-26 DE DE69318077T patent/DE69318077T2/de not_active Expired - Fee Related
- 1993-07-26 AT AT93305864T patent/ATE165360T1/de not_active IP Right Cessation
- 1993-07-27 UA UA93003172A patent/UA37181C2/uk unknown
- 1993-07-27 US US08/097,205 patent/US5407929A/en not_active Expired - Fee Related
- 1993-07-28 AU AU44227/93A patent/AU657866B2/en not_active Ceased
- 1993-07-28 CA CA002101502A patent/CA2101502A1/en not_active Abandoned
- 1993-07-28 HU HU9302194A patent/HU219637B/hu not_active IP Right Cessation
- 1993-07-28 IL IL106516A patent/IL106516A/en not_active IP Right Cessation
- 1993-07-29 PL PL93317972A patent/PL172830B1/pl unknown
- 1993-07-29 FI FI933391A patent/FI933391L/fi unknown
- 1993-07-29 PH PH46601A patent/PH30109A/en unknown
- 1993-07-29 NZ NZ24828593A patent/NZ248285A/en unknown
- 1993-07-29 PL PL93299870A patent/PL172835B1/pl unknown
- 1993-07-30 NO NO932745A patent/NO303734B1/no unknown
- 1993-07-30 RU RU93047027/04A patent/RU2118959C1/ru not_active IP Right Cessation
- 1993-07-30 MX MX9304611A patent/MX9304611A/es unknown
- 1993-07-30 ZA ZA935529A patent/ZA935529B/xx unknown
- 1993-07-30 KR KR1019930014742A patent/KR100245938B1/ko not_active Expired - Fee Related
- 1993-07-30 BR BR9303235A patent/BR9303235A/pt not_active Application Discontinuation
- 1993-07-31 CN CN93117437A patent/CN1037683C/zh not_active Expired - Fee Related
-
1998
- 1998-04-23 GR GR980400753T patent/GR3026699T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
RU2186778C2 (ru) | Натриевая соль омепразола формы б, способ ее получения (варианты) и фармацевтический препарат, содержащий натриевую соль омепразола формы б | |
SA97180739B1 (ar) | الشكل البللوري للمتشاكل S - enantiomer للأومبرازول omeprazole | |
JPH0255437B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
NL192266C (nl) | Werkwijze voor het bereiden van een kristallijn cefepime-dihydrochloride alsmede het kristallijne dihydrochloride en mengsels die het bevatten. | |
JP2009143957A (ja) | アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム | |
ES2390611T3 (es) | Agente de erradicación de Helicobacter pylori que tiene actividad inhibidora sobre la secreción de ácido gástrico | |
TWI293631B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
DK163514B (da) | Fremgangsmaade til fremstilling af en krystallinsk form af natriumsaltet af et oximderivat af 7-aminothiazolylacetamidocephalosporansyre | |
SE449996B (sv) | (6r,7r)-7-/(z)-2-(2-aminotiazol-4-yl)-2-(2-karboxiprop-2-oxiimino)acetamidol/-3-(1-pyridiniummetyl)cef-3-em-4-karboxylat i form av en kristallin bishydroklorid farmaceutisk komposition derav samt anvendning som mellanpr | |
JPS62294615A (ja) | 抗菌剤 | |
JP2575590B2 (ja) | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 | |
JPH0741484A (ja) | セフェム化合物及び抗菌剤 | |
CA2082472A1 (en) | Crystalline form of a cephalosporin antibiotic | |
FR2884822A1 (fr) | Derives de triazines, leur preparation et leur application en therapeutique | |
HU204271B (en) | Process for producing cristalline 1-carba-dethia-cepheme-solvates | |
US10717729B2 (en) | Thiamine-organic acid salt | |
SU973024A3 (ru) | Способ получени аддитивных солей пивалоилоксиметилового эфира 7 @ -[2-(2-аминотиазол-4-ил) ацетамидо]-3-[1-(2-диметиламиноэтил)-1н-тетразол-5-илтиометил]-3-цефем-4-карбоновой кислоты с сол ной,винной или лимонной кислотой | |
FR2952M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
RU2785195C1 (ru) | Способ получения полиморфной формы 4-(3-этокси-4-гидроксибензил)-N-(2,4-дифторфенил)-5-оксо-5,6-дигидро-4H-1,3,4-тиадиазин-2-карбоксамида | |
US20110118462A1 (en) | N-heterocyclic substituent-containing antibiotic, preparation and use thereof | |
US3682953A (en) | Substituted 5-nitrofuryl-pyrazoles | |
JPH04234880A (ja) | β−ラクタム抗生物質の結晶性塩酸塩 | |
US3835165A (en) | Nitrofuryl-alpha-halo-hydrazones | |
WO2017142002A1 (ja) | C-4"位置換マクロライド化合物フリー体及び塩の結晶形並びにそれらの製造方法 |